MAPK1 and cancer: Of these, Sprouty2 (SPRY2) and Sprouty4 (SPRY4) are downregulated compared to the corresponding non-tumor tissues, suggesting that they act as tumor suppressors in cancer via suppressing the MAPK/ERK signaling pathway [30].